A departing director will stay with BetterLife Pharma as an adviser.
BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) announced Tony Pullen's resignation from its board, effective November 4, 2026, and his continued role as an advisor. Henry Chow, CPA, CA, was appointed as a new director. Pullen brought life sciences investment experience, while Chow has extensive public company audit experience. The company is developing BETR-001 for chronic cluster headache and chronic migraine.
How this was made
The 30-second read
Market read
Governance change with limited immediate market impact.
Timing
effective today
Background
Board member resignation and appointment at BetterLife Pharma, a Canadian biotech developing BETR-001.
Market effects
minimal effect on biotech sector
limited to Canadian market
none
Key entities
- companyBetterLife Pharma Inc.
Emerging biotechnology company listed on CSE (BETR) and OTCQB (BETRF).
- personTony Pullen
Resigned from board, remains advisor.
- personHenry Chow
Appointed new director.

